Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc R Theoret

Showing results (21-30 of 111) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review ProgramR Angelo de Claro, Jennifer J Gao, Tamy Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2025
FDA Approval Summary: Blinatumomab for the Treatment of B-cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase ChemotherapyCara A Rabik, Shu Wang, Ritu Chadda, et al.
Immunology|June 13, 2006
Cross-priming utilizes antigen not available to the direct presentation pathwayKeri B Donohue, Jean M Grant, Eric F Tewalt, et al.
Seminars in Cancer Biology|April 3, 2002
Assumptions of the tumor 'escape' hypothesisNicholas P Restifo, Paul A Antony, Steven E Finkelstein, et al.
Plos One|October 27, 2025
Machine learning reveals distinct T-cell receptor clusters in plasma cell dyscrasias compared to healthy controlsDavid G Coffey, Yong Zhang, Elizabeth Hill, et al.
Clinical Trials (London, England)|March 19, 2019
Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directionsBellinda L King-Kallimanis, Lynn J Howie, Jessica K Roydhouse, et al.
Blood|May 10, 2024
Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemiaRobert Q Le, Donna Przepiorka, Haiyan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAF<sup>V600</sup> Wild-Type Unresectable or Metastatic MelanomaJulia A Beaver, Marc R Theoret, Sirisha Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2024
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell LymphomaMona Elmacken, Helkha Peredo-Pinto, Cong Wang, et al.
The Journal of Clinical Investigation|October 28, 2010
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceDhanalakshmi Chinnasamy, Zhiya Yu, Marc R Theoret, et al.
Pageof 12

Showing results (21-30 of 111) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review ProgramR Angelo de Claro, Jennifer J Gao, Tamy Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2025
FDA Approval Summary: Blinatumomab for the Treatment of B-cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase ChemotherapyCara A Rabik, Shu Wang, Ritu Chadda, et al.
Immunology|June 13, 2006
Cross-priming utilizes antigen not available to the direct presentation pathwayKeri B Donohue, Jean M Grant, Eric F Tewalt, et al.
Seminars in Cancer Biology|April 3, 2002
Assumptions of the tumor 'escape' hypothesisNicholas P Restifo, Paul A Antony, Steven E Finkelstein, et al.
Plos One|October 27, 2025
Machine learning reveals distinct T-cell receptor clusters in plasma cell dyscrasias compared to healthy controlsDavid G Coffey, Yong Zhang, Elizabeth Hill, et al.
Clinical Trials (London, England)|March 19, 2019
Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directionsBellinda L King-Kallimanis, Lynn J Howie, Jessica K Roydhouse, et al.
Blood|May 10, 2024
Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemiaRobert Q Le, Donna Przepiorka, Haiyan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAF<sup>V600</sup> Wild-Type Unresectable or Metastatic MelanomaJulia A Beaver, Marc R Theoret, Sirisha Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2024
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell LymphomaMona Elmacken, Helkha Peredo-Pinto, Cong Wang, et al.
The Journal of Clinical Investigation|October 28, 2010
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceDhanalakshmi Chinnasamy, Zhiya Yu, Marc R Theoret, et al.
Pageof 12